Dopamine is believed to contribute to the degeneration of dopamine-containing neurons in the brain. However, whether dopamine affects the survival of other neuronal populations has remained unclear. Here we document that mice with persistently elevated extracellular dopamine, resulting from inactivation of the dopamine transporter gene, sporadically develop severe symptoms of dyskinesia concomitant with apoptotic death of striatal dopamineresponsive ␥-aminobutyric acidergic neurons. Chronic inhibition of dopamine synthesis prevents the appearance of motor dysfunction. The neuronal death is associated with overactivation of dopaminergic signaling as evidenced by the robust up-regulation of striatal ⌬FosB, cyclin-dependent kinase 5, and p35. Moreover, hyperphosphorylation of the tau protein, a phenomenon associated with the activation of cyclin-dependent kinase 5 in several neurodegenerative disorders, is observed in symptomatic mice. These findings provide in vivo evidence that, in addition to its proposed role in the degeneration of dopamine neurons, dopamine can also contribute to the selective death of its target neurons via a previously unappreciated mechanism. I n the central nervous system, the neostriatum is densely innervated by dopaminergic neurons that originate from the substantia nigra. Despite the high concentrations of dopamine (DA) physiologically present in the striatum, there is increasing evidence that DA can also be toxic after pharmacological manipulations that disrupt both intra-and extracellular DA dynamics. In particular, the toxicity of DA to nigrostriatal dopaminergic terminals has been extensively studied (1-4). Some observations suggest that striatal DA could contribute to the demise of not only DA-containing neurons but also of other neuronal populations (5). However, whether chronically elevated extracellular DA can affect postsynaptic striatal neurons in a physiologically relevant situation, and what would be the mechanism of such toxicity, has essentially remained unexplored.
I
n the central nervous system, the neostriatum is densely innervated by dopaminergic neurons that originate from the substantia nigra. Despite the high concentrations of dopamine (DA) physiologically present in the striatum, there is increasing evidence that DA can also be toxic after pharmacological manipulations that disrupt both intra-and extracellular DA dynamics. In particular, the toxicity of DA to nigrostriatal dopaminergic terminals has been extensively studied (1) (2) (3) (4) . Some observations suggest that striatal DA could contribute to the demise of not only DA-containing neurons but also of other neuronal populations (5) . However, whether chronically elevated extracellular DA can affect postsynaptic striatal neurons in a physiologically relevant situation, and what would be the mechanism of such toxicity, has essentially remained unexplored.
A persistent hyperdopaminergic tone has been demonstrated in the striatum of DA transporter knockout (DAT-KO) mice. Particularly, a 5-fold elevation in striatal extracellular DA concentration and locomotor hyperactivity have been documented in these mice (6) (7) (8) (9) . Previous attempts to assess the potential neurotoxic effect of high extracellular DA in DAT-KO mice have concentrated on the presynaptic dopaminergic neurons but have not revealed any significant degeneration (9, 10) . However, a higher mortality rate has been noted in DAT-KO mice (6) , suggesting that the hyperdopaminergic tone may affect other neuronal populations. In the present study, we document that a subpopulation of DAT-KO mice sporadically develop symptoms of dyskinesia along with striatal neuronal death, in which neurons receiving dopaminergic input are mainly affected. In addition, we provide evidence that sustained dopaminergic signaling in association with hyperphosphorylation of tau is associated with the selective neuronal death.
Ϫ80°C before protein extraction. Tissues were homogenized in a Tris͞SDS͞urea buffer (50 mM Tris, pH 7.5͞50 mg/ml SDS͞8 M urea) complemented with leupeptin (5 g͞ml), calpastatin (500 nM) and a mixture of protease inhibitors (Sigma). Protein concentrations were measured by using a DC-protein assay (Bio-Rad). Equal amounts of proteins (10-50 g) were separated on SDS͞10% PAGE and transferred to nitrocellulose membranes. Proteins were detected by using primary antibodies directed against cyclin-dependent kinase 5 (cdk5), p35, FosB (Santa Cruz Biotechnology), actin, Tau 1, vesicular monoamine transporter (VMAT2) (Chemicon), AT-8 (Innogenetics), and PHF-1. Preparation of the cytoskeletal insoluble proteins was carried out by using the following protocol. Tissues were homogenized at 4°C in a buffer containing Tris (10 mM), NaCl (150 mM), EDTA (1 mM), Triton X-100 (1% wt͞vol), and a protease inhibitor mixture (Sigma). The homogenates were then centrifuged at 14,000 ϫ g for 15 min at 4°C. The supernatants (soluble fraction) were collected and kept for further use. The pellets (insoluble fraction) were resuspended in a volume of SDS͞urea buffer equivalent to the volume of the soluble fraction.
Statistical Analysis. Student's two-tailed t test was used for statistical comparisons between two groups, and one-factor ANOVA followed by post hoc Newman-Keuls test, when appropriate, was used for comparisons between more than two groups by using PRISM version 2.0 (Abacus Concepts, Berkeley, CA).
For description of HPLC protocol, ␣-methyl-p-tyrosine (AMPT) treatment, Nissl staining protocol, terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) assays, stereology techniques for evaluation of cell counts, cdk5 activity assay and microarray analysis, see Supporting Text, which is published as supporting information on the PNAS web site, www.pnas.org.
Results
Symptoms of Dyskinesia in DAT-KO Mice. Over a 7-year period of working with the DAT-KO mouse colony, we consistently observed higher mortality rate of DAT-KO mice at all ages in comparison to heterozygotes and WT littermates. In a controlled study, we documented a mortality rate of 36% in a cohort of 65 DAT-KO mice followed daily over a period of 1 year after birth. The loss of these mice occurred sporadically and was preceded by the appearance of progressive symptoms of motor dysfunction. These symptoms were easily recognizable in DAT-KO mice a few weeks before death by standard behavioral tests. The earliest manifestation of these symptoms was an abnormal extension of the hindlimbs during a 15-s period of tail suspension. Invariably, these mice progressed to more intense clasping, which at the limit developed as a constant full body clasp ( Fig.  1 A and B) (11) .
Gait abnormalities followed the development of clasping behavior in the symptomatic DAT-KO mice. These ataxic symptoms were assessed by footprint analysis method and three parameters were measured: (i) step length, the number of steps made during a constant walking distance; (ii) gait width, the average lateral distance between opposite left and right hindlimbs of a given step; and (iii) the alternation coefficient in which alternate steps of normal animals would fall exactly equidistant between the preceding and succeeding opposite steps (Fig. 1C) . All three parameters were severely affected in the symptomatic DAT-KO mice (Fig. 1 D-F) . These gait abnormalities, and the gait width in particular, are similar in character to those observed in mouse models of striatal neurodegeneration (11, 13) , but are different from those reported for cerebellar ataxia (14) .
Finally, the symptomatic DAT-KO mice reached an end stage, characterized by the emergence of tremor, rapid weight loss, and pronounced dorsal kyphosis (hunchback posture) (Fig. 1G) .
Moreover, the most salient feature of DAT-KO mice, their locomotor hyperactivity in response to a novel environment (6, 8) , was markedly curtailed at this stage (Fig. 1H) . Note that symptomatic DAT-KO mice were defined and selected for characterization only when they have developed motor dysfunction, gait and posture abnormalities.
Inhibition of DA Synthesis Prevents the Development of Symptoms.
To directly assess whether DA is critical to development of the phenotype, 18 DAT-KO mice were chronically depleted from DA by inhibiting TH, the rate-limiting enzyme for DA synthesis, by using AMPT, and their clasping behavior was compared with a cohort of 18 saline-treated DAT-KO mice. Whereas in normal mice, AMPT treatment (100 mg͞kg) results in only partial depletion of DA, the lack of a reuptake mechanism makes the DAT-KO mice extremely sensitive to this treatment (8, 9, 15, 16) . In DAT-KO mice, acute treatment with this drug essentially eliminates DA storage and release as well as immobilizes the mice for Ͼ8 h, followed by recovery. Within the saline-treated DAT-KO mice cohort, five mice demonstrated a progressive increment in clasping behavior during a 40-week observation period, which was reflected by an average clasping score of 1.79 Ϯ 0.30 for the entire cohort. On the other hand, all DAT-KO mice chronically treated with AMPT, once every 3 days, did not show progression of clasping score after the same time period (0.58 Ϯ 0.13, P Ͻ 0.05, Student's two-tailed t test) as compared with saline-treated group ( Fig. 2A) . Furthermore, in contrast to the saline-treated group, no mortality was observed in AMPT-treated DAT-KO mice (Fig. 2B ).
Loss of Striatal Dopaminoceptive GABAergic Neurons.
The behavioral manifestations in the symptomatic DAT-KO mice are suggestive of striatal dysfunction. To explore whether signs of neuronal damage were present in the brain of end stage symptomatic DAT-KO mice, we initially evaluated astrocytosis as an indirect marker of neurodegeneration (17) . Staining for GFAP revealed a 7-fold increase in the number of reactive striatal astrocytes in symptomatic DAT-KO mice compared with WT littermates, whereas only a 2-fold increase in their number was found in asymptomatic DAT-KO mice ( Fig. 3 A and B) . GFAP cell counts in the cerebral cortex ( Fig. 3C ), which also contains dopaminergic terminals, or in other potentially affected regions such as globus pallidus and substantia nigra pars reticulata were not different between the three groups of mice (data not shown). Thus, the reactive astrocytosis seen in symptomatic DAT-KO mice suggests a selective vulnerability of the striatum.
Immunohistochemistry using selective antibody directed against TH failed to reveal any differences in the number of dopaminergic cell bodies between asymptomatic and symptomatic DAT-KO littermates in the substantia nigra pars compacta (Fig. 4 A and B) . Furthermore, Western blot analysis of the VMAT2 levels, a marker of presynaptic DA terminals, revealed no change in the levels of this protein in striatal extracts of both groups of mice (Fig. 4C) . Finally, total tissue DA levels in the striatum were not different between asymptomatic and symptomatic DAT-KO mice (asymptomatic: 1.05 Ϯ 0.12 ng͞mg of wet tissue; symptomatic: 1.36 Ϯ 0.26 ng͞mg of wet tissue; P ϭ 0.878; Student's two-tailed t test). Note also that, in agreement with previous studies (9, 10) , only minor reductions in the number of TH-positive cells and striatal VMAT2 levels were observed in asymptomatic DAT-KO compared with WT mice, supporting a lack of apparent degeneration of DA neurons in these mutants (Fig. 4 B and C) . Thus, by using three independent markers, no evidence of additional changes in striatal presynaptic DA neurons was found in the symptomatic DAT-KO mice when compared with asymptomatic DAT-KO mice.
In contrast, analysis of the anatomical integrity of postsynaptic striatal neurons did reveal significant cell loss in symptomatic versus asymptomatic DAT-KO mice. Nissl staining (cresyl violet) in brain sections revealed a significant loss of striatal cells in symptomatic DAT-KO mice (403 Ϯ 12 cells per mm 2 ), whereas no apparent differences between WT (571 Ϯ 14 cells per mm 2 ) and asymptomatic DAT-KO littermates (532 Ϯ 7 cells per mm 2 ) were observed (P Ͻ 0.01 vs. WT and P Ͻ 0.05 vs. asymptomatic DAT-KO mice; one-factor ANOVA and post hoc NewmanKeuls test; n ϭ 4 mice per group). The mean striatal total volumes from bregma, ϩ0.50 mm to ϩ0.02 mm, which correspond to the part of striatum where the sections used for histological studies have been collected, were not statistically different between groups of mice (asymptomatic DAT-KO mice: 5.01 Ϯ 0.07 mm 3 , P ϭ 0.1935; sypmtomatic DAT-KO mice: 5.04 Ϯ 0.12 mm 3 , P ϭ 0.3186 versus WT: 5.19 Ϯ 0.07 mm 3 ; one-factor ANOVA and post hoc Newman-Keuls test; n ϭ 8 mice per group). More specific assessment of striatal neuronal loss was carried out. Staining for choline acetyltransferase by immunofluorescence indicated that the numbers of cholinergic neurons were not significantly altered between the three groups of mice (Fig. 4D) . On the other hand, we observed a concomitant decrease of Ϸ30% and Ϸ25%, respectively, in the number of glutamic acid decarboxylase and DARPP-32-positive neurons in the symptomatic DAT-KO mice when compared with asymptomatic DAT-KO and WT littermates (Fig. 4 E-G) . Glutamic acid decarboxylase and DARPP-32 are known to identify the majority of striatal GABAergic medium spiny neurons (18) .
Markers of Cell Death Confirm Striatal Neuronal Loss.
To assess whether the decrease in the number of striatal GABAergic neurons might result from a cell death process in the symptomatic DAT-KO mice, we performed a TUNEL assay. Positive staining was found in the striatum of the symptomatic DAT-KO mice, indicating a fragmentation of DNA in striatal cells (6 Ϯ 2 positive striatal cells per coronal section, values represent the average of five sections per animal Ϯ SEM, n ϭ 4) (Fig. 4H) . Also, we used a selective antibody directed against the cleaved p17 fragment of caspase-3, another marker of the apoptotic process, to confirm occurrence of cell death in the striatum of the symptomatic DAT-KO mice (9 Ϯ 2 positive striatal cells per coronal section, values represent the average of five sections per animal Ϯ SEM, n ϭ 4) (Fig. 4I) . Further characterization using anti-NeuN antibody and Hoechst dye 33342 confirmed the neuronal nature of TUNEL-positive cells and their occurrence with condensed chromatin, one hallmark of apoptotic death (Fig. 4 J and K) . Moreover, we demonstrated that activated caspase-3 immunoreactive cells where, in fact, DARPP-32-positive medium spiny neurons (Fig. 4L) . No positive cells were observed for either TUNEL or activated caspase-3 in asymptomatic DAT-KO (Fig. 4 H and I) or WT littermates (data not shown).
Enhanced Dopaminergic Signaling and Hyperphosphorylation of Tau
in Symptomatic DAT-KO Mice. To identify potential biochemical pathways associated with hyperdopaminergic tone and neuronal degeneration, we performed a series of biochemical experiments. Previous studies have demonstrated that chronic exposure to the indirect DA agonist cocaine increases the expression of cdk5 and its coactivator p35 through, at least in part, an accumulation of the stable transcription factor ⌬FosB (19, 20) . Up-regulation of cdk5 activity has been linked to neurodegeneration (21) (22) (23) (24) . Results from Affymetrix Mu74 DNAChips (containing 12,422 genes and ESTs) revealed that the hyperdopaminergic tone in the asymptomatic DAT-KO mice leads to an increase of 1.3-and 1.6-fold in the levels of cdk5 and p35, respectively. The mRNA levels of other candidate kinases that could also potentially be associated with neurodegenerative processes were either unchanged or decreased in DAT-KO mice (see Table 1 , which is published as supporting information on the PNAS web site). These results have been confirmed by Western blot analysis showing that the levels of ⌬FosB, cdk5, and p35 were increased by Ϸ2.0-, 1.5-, and 1.5-fold, respectively, over the levels measured in their WT littermates (n ϭ 3-8 mice per group; Fig. 6 , which is published as supporting information on the PNAS web site). More importantly, in striatal extracts of symptomatic DAT-KO mice, the levels of ⌬FosB, cdk5, and p35 were further increased by Ϸ2.5-, 2.0-, and 3.0-fold, respectively, over the levels found in asymptomatic DAT-KO littermates ( Fig.  5 A and B) . When compared with WT mice, the overall increase in cdk5 and p35 in the symptomatic DAT-KO mice is Ϸ4-to 6-fold. Moreover, an immunoprecipitation kinase assay using histone H1 as substrate showed a 2-fold increase of cdk5 activity in the striatum of symptomatic as compared with asymptomatic DAT-KO mice (Fig. 5C ). This increase in cdk5 activity did not seem to involve the cleavage of p35 to p25, which has been implicated in neurodegenerative processes (21, 22) , because p25 was not detected in striatal extract of symptomatic DAT-KO mice (Fig. 7 , which is published as supporting information on the PNAS web site).
Abnormal phosphorylation of the microtubule-associated protein tau is a known pathological outcome of cdk5 dysregulation and is associated with neurodegenerative conditions such as Alzheimer's disease (21, 22, 25) . The presence of hyperphosphorylated tau isoforms in the striatum of symptomatic DAT-KO mice was thus investigated by using three phosphorylation-state-dependent antibodies raised against different cdk5-phosphorylated epitopes: Tau 1, which recognizes dephosphorylated serine 199 and 202; AT-8, which recognizes the phosphorylated form of the same residues; and PHF-1, which recognizes phosphoserine 396. Immunostaining of Western blots using Tau1 revealed an obvious decrease in the levels of unphosphorylated tau isoforms, while at the same time AT-8 and PHF-1 showed the appearance of hyperphosphorylated tau isoforms in the symptomatic DAT-KO mice (Fig. 5D) . Importantly, densitometric analysis showed that the amount of hyperphosphorylated tau measured in these mice also correlated with the levels of cdk5 (r 2 ϭ 0.89, P Ͻ 0.02, n ϭ 5) and p35 (r 2 ϭ 0.78; P Ͻ 0.02, n ϭ 6; Pearson's correlation analysis). These data suggest that, in symptomatic DAT-KO mice, the considerable up-regulation of cdk5 and p35 might be one contributing factor leading to hyperphosphorylation of tau. It is noteworthy that an increase of Ϸ1.5-fold in the level of cdk5 and p35 proteins, such as observed in the asymptomatic DAT-KO mice, was not sufficient to promote tau phosphorylation. This latter observation is in agreement with results obtained from cdk5͞p35 double transgenic mice in which moderate overexpression of the limiting cofactor of cdk5 activity, p35 (Ϸ1.5-fold), did not lead to tau hyperphosphorylation (26) .
In an attempt to determine the physical nature of hyperphosphorylated tau in symptomatic DAT-KO mice, we isolated Triton X-100 soluble and insoluble protein fractions from striatal homogenates. Western blot analysis of these fractions by using Tau-1 and AT-8 antibodies confirmed the presence of hyperphosphorylated tau in the soluble fraction of symptomatic DAT-KO mice, but did not reveal the presence of insoluble tau (Fig. 5E) . Further examination by electron microscopy also failed to demonstrate the occurrence of neurofibrillary tangles in the perikarya of GABAergic medium spiny neurons in symptomatic DAT-KO mice (data not shown). However, immunofluorescence analysis demonstrated that hyperphosphorylated tau proteins, recognized by AT-8 antibody, accumulated in the cytoplasm of striatal neurons but not in cortical neurons of the symptomatic DAT-KO mice (Fig. 5F ). To date, evidence exists that either neurofibrillary tangles or soluble accumulation of hyperphosphorylated tau may contribute to cell death (25) .
Discussion
Most of the studies on DA-induced neurodegeneration recognize a role of DA in damage to presynaptic dopaminergic terminals (1) (2) (3) (4) . This toxicity of DA is thought to be primarily caused by dysregulation of intracellular DA compartmentalization (4). In our study, no evidence of degeneration of DA neurons is observed in either asymptomatic or symptomatic DAT-KO mice. Despite the fact that protection of DA neurons can be potentially explained by peculiarities of DA homeostasis in these mice (6) (7) (8) (9) 27) , these data suggest that dopaminergic terminals are resistant to the adverse effects of persistently elevated extracellular DA. Rather, our results demonstrate that DA contributes to degeneration of striatal postsynaptic neurons when its extracellular levels are increased in vivo. A similar contention, that DA could play a role in the death of postsynaptic striatal neurons, has been suggested previously (5) . However, these studies have examined the effects of DA on striatal neuronal integrity after triggers of neuronal injury such as ischemia, mitochondrial toxins, intrastriatal injection of Nmethyl-D-aspartate or kainic acid (28) (29) (30) (31) . Taken together, these observations suggest that dopaminergic terminals might be more vulnerable to dysregulation of intracellular DA, whereas extracellular excess of DA affects a postsynaptic neuronal population.
The accumulation of ⌬FosB, in conjunction with the robust up-regulation of cdk5 and p35 as well as the accumulation of hyperphosphorylated tau, suggest a novel mechanism of DAinduced neuronal toxicity, by sustained intracellular signaling. It is well established that an accumulation of ⌬FosB and cdk5 results from chronic activation of DA receptors (19, 20) . Moreover, up-regulation of cdk5 activity leading to hyperphosphorylation of tau and cell death, through disruption of the neuronal cytoskeleton, is well documented (21) (22) (23) (24) . However, the mechanism by which cdk5 contributes to cell death is not fully elucidated, and alteration of cdk5 function in response to elevated extracellular DA concentrations has not been previously reported in the context of neuronal degeneration. Our data suggest that an Ϸ4-to 6-fold increase of cdk5 and p35 levels in GABAergic neurons can lead to an aberrant phosphorylation of tau and neuronal death. Interestingly, a recent in vitro study documented that hyperphosphorylated tau can induce apoptotic cell death, characterized by chromatin condensation, DNA fragmentation, and caspase-3 activation, in the absence of detectable protein aggregates, which is similar to our observations in the striatum of symptomatic DAT-KO mice (32) .
The precise biochemical pathways underlying the upregulation of cdk5 and p35 as well as their role in the neurodegeneration observed in DAT-KO mice will require further characterization. It is possible that other mechanisms, such as oxidative stress or excitotoxicity in response to elevated DA, may also contribute to the up-regulation of cdk5 and͞or directly to striatal neuronal loss. However, because cdk5 is a known downstream target of ⌬FosB (19, 20) , the accumulation of ⌬FosB in the striatum of symptomatic DAT-KO mice in response to elevated extracellular DA is likely a contributing factor to the up-regulation of cdk5 gene expression. Interestingly, D1 receptor stimulation and treatment with the antipsychotic haloperidol, both recognized to induce ⌬FosB (19, 33) , have been shown to be associated with hyperphosphorylation of another substrate of cdk5, the microtubule-associated protein MAP2 (34, 35) .
The association of ⌬FosB with neuronal loss in DAT-KO mice raises the question as to whether aberrant dopaminergic neurotransmission leading to accumulation of ⌬FosB in striatal neurons might trigger, or be a susceptibility factor for, human neurodegenerative processes. For example, in some long-term cocaine and amphetamine abusers, choreoathetotic dyskinesias and gait abnormalities have been observed (36) (37) (38) . An accumulation of ⌬FosB has also been noted in striatal neurons of patients with, or in animal models of, Parkinson's disease treated with L-DOPA (39, 40) , in which degeneration of GABAergic medium spiny neurons has been suspected to underlie the development of dyskinesia (40) (41) (42) . Furthermore, several features of the symptomatic DAT-KO mice resemble those described in mouse models of Huntington's disease (11, 13) . Because DA is suspected to play a role in the pathophysiology of this disorder (5, 43) , it would be of interest to explore whether some of the alterations in DA receptor signaling observed here might be relevant to this pathology. 
